CD8A and neoplasm: Specifically, Dai et al. have tested the co-administration of a Notch inhibitor (DAPT) and an anti-PD-L1 antibody in pancreatic cancer mouse models, which resulted in significant inhibition of tumor growth compared to monotherapy, induced PD-L1 overexpression, and increased number of tumor-infiltrating CD8+ T cells [165].